Please assess the completion status of the following clinical trial:

Trial Title: 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with a diagnosis of type 2 diabetes mellitus~* either treatment-naïve or on a maximum of 1 oral antidiabetic therapy on a stable dose for the10 weeks prior to screening~* HbA1c ≥6.5 to ≤9.0% and for treatment-naïve patients:HbA1c \>7.0 to ≤10.0%~* HbA1c \>7.0 to ≤10.0% at Visit 2 (start of run-in) for all patients~* Age between 18 and 80 years~* BMI less than 40 kg/m2~* Signed and dated informed consent prior to admission to the study in accordance with GCP and local legislation~Exclusion Criteria:~1. Myocardial infarction, stroke or TIA within 6 months prior to informed consent~2. Impaired hepatic function~3. Renal insufficiency or impaired renal function~4. Disease of central nervous system, or psychiatric disorders or clinically relevant neurologic disorders that may interfere with trial participation~5. Chronic or clinically relevant acute infections~6. Current or chronic urogenital tract infection determined by medical history~7. History of clinically relevant allergy/hypersensitivity~8. Treatment with glitazones, GLP-1 analogues or insulin within 3 months prior to informed consent~9. Treatment with anti obesity drugs~10. Current treatment with systemic steroids~11. Alcohol abuse~12. Treatment with an investigational drug within 2 months prior to informed consent~13. known intolerance to metformin~14. Dehydration~15. Unstable or acute CHF~16. Acute or chronic acidosis~17. Hereditary galactose intolerance~18. Woman of child bearing potential who are nursing or pregnant or not practicing an acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).